全文获取类型
收费全文 | 11724篇 |
免费 | 703篇 |
国内免费 | 110篇 |
专业分类
耳鼻咽喉 | 79篇 |
儿科学 | 354篇 |
妇产科学 | 174篇 |
基础医学 | 1330篇 |
口腔科学 | 476篇 |
临床医学 | 1056篇 |
内科学 | 2759篇 |
皮肤病学 | 271篇 |
神经病学 | 897篇 |
特种医学 | 567篇 |
外科学 | 2030篇 |
综合类 | 49篇 |
一般理论 | 1篇 |
预防医学 | 677篇 |
眼科学 | 111篇 |
药学 | 580篇 |
中国医学 | 12篇 |
肿瘤学 | 1114篇 |
出版年
2023年 | 140篇 |
2022年 | 242篇 |
2021年 | 473篇 |
2020年 | 231篇 |
2019年 | 356篇 |
2018年 | 435篇 |
2017年 | 296篇 |
2016年 | 288篇 |
2015年 | 331篇 |
2014年 | 431篇 |
2013年 | 527篇 |
2012年 | 755篇 |
2011年 | 847篇 |
2010年 | 477篇 |
2009年 | 447篇 |
2008年 | 711篇 |
2007年 | 689篇 |
2006年 | 663篇 |
2005年 | 638篇 |
2004年 | 557篇 |
2003年 | 516篇 |
2002年 | 419篇 |
2001年 | 218篇 |
2000年 | 202篇 |
1999年 | 155篇 |
1998年 | 99篇 |
1997年 | 84篇 |
1996年 | 71篇 |
1995年 | 55篇 |
1994年 | 61篇 |
1993年 | 48篇 |
1992年 | 116篇 |
1991年 | 92篇 |
1990年 | 83篇 |
1989年 | 79篇 |
1988年 | 61篇 |
1987年 | 54篇 |
1986年 | 65篇 |
1985年 | 52篇 |
1984年 | 43篇 |
1983年 | 47篇 |
1982年 | 27篇 |
1979年 | 30篇 |
1978年 | 23篇 |
1977年 | 29篇 |
1975年 | 24篇 |
1974年 | 31篇 |
1973年 | 23篇 |
1968年 | 23篇 |
1967年 | 19篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
111.
Mario Sanna Yogesh Jain Giuseppe De Donato Lorenzo RohitLauda Abdelkader Taibah 《Otology & neurotology》2004,25(5):797-804
OBJECTIVE: The objective of this study was to review the outcome of surgical management in patients of jugular paragangliomas. STUDY DESIGN: We conducted a retrospective case review. SETTING: Tertiary care otology and skull base center. MATERIALS AND METHODS: Fifty-five patients with the diagnosis of a jugular paraganglioma (Fisch Class C and D Glomus Jugulare) were managed over a period of 15 years. All patients with adequate follow up and complete records (53 cases) were reviewed with emphasis on the results of surgical management and the factors influencing them. INTERVENTION: All 53 patients were managed with a view to surgically extirpate the tumor. The primary approach was the infratemporal fossa approach-Type A used in the majority of the patients. In eight cases, the procedure was staged owing to the presence of large intracranial extension. Three patients required additional procedures to ameliorate the after-effects of lower cranial nerve resection. RESULTS: Gross total tumor removal was achieved in 49 patients. There were five cases of recurrence. Coupled with the residual tumors in five patients, the surgical control achieved was 83%. There was no perioperative mortality. There were two cases of postoperative cerebrospinal fluid leak, both of which required surgical exploration and closure. The facial nerve was resected in seven patients. The overall preservation rate of clinically uninvolved lower cranial nerves was 75%. CONCLUSIONS: The low level of complications along with a high surgical control achieved makes surgery the primary mode of treatment in the vast majority of these tumors, regardless of the size and location. 相似文献
112.
113.
114.
115.
116.
Justo Lorenzo Bermejo Kari Hemminki 《Cancer epidemiology, biomarkers & prevention》2005,14(7):1738-1740
BACKGROUND: Tobacco smoking is the principal cause of lung cancer. The risk of lung cancer in the offspring of lung cancer patients is about twice higher than the risk in the general population. The present study investigated the contribution of shared smoking habits to the familial clustering of lung cancer. METHODS: We estimated the relative risk of lung cancer attributable to smoking according to the extent to which smokers transmit their smoking habits to the offspring (heritability of smoking), the prevalence of smoking in the general population, and the risk of lung cancer for smokers compared with nonsmokers. FINDINGS: The relative risk of lung cancer for the offspring of lung cancer patients attributable to smoking was 1.19 when published data on smoking practice were modeled (i.e., assuming that the heritability of smoking was 0.5, the smoking prevalence 40%, and the odds ratio of lung cancer for smokers versus nonsmokers was 20). INTERPRETATION: Most familial cases of lung cancer cannot be attributed to shared smoking habits. The example of smoking can be used for other familial cancers, for which no strong environmental risk factors are usually known, to infer the primary role for heritable genes. 相似文献
117.
118.
Andrea Rocca Roberta Maltoni Alessandro Passardi Ilaria Massa Michele Aquilina Ruggero Ridolfi Toni Ibrahim Lorenzo Cecconetto Samanta Sarti Elisabetta Pietri Oriana Nanni Dino Amadori 《Cancer chemotherapy and pharmacology》2010,65(5):871-876
Purpose
Anthracyclines and fluoropyrimidines are very active in breast cancer, while liposomal doxorubicin has low cardiotoxicity. We conducted a dose-finding study of the combination of liposomal doxorubicin and capecitabine in patients with pretreated metastatic breast cancer.Patients and methods
Patients received liposomal doxorubicin 60 mg/m2 on day 1 plus capecitabine 825 mg/m2 bid (level 0) or 1,000 mg/m2 bid (level 1) on days 1–14 of each 21-day cycle to establish the maximum tolerated dose (MTD) and cardiac safety.Results
Nine patients were enrolled and a total of 52 courses were delivered (median 6 cycles per patient [range 4–7]). Grade 4 neutropenia occurred in 15% of cycles, with one episode of febrile neutropenia; most nonhematological toxicities were mild or moderate. No formal MTD was established, and the study was closed because two cardiac events were observed at dose level 1 and another at dose level 0 in patients pretreated with epirubicin ≥ 560 mg/m2.Conclusions
The recommended dose for phase II studies is liposomal doxorubicin 60 mg/m2 on day 1 plus capecitabine 825 mg/m2/bid on days 1–14 of each 21-day cycle. Despite the lower cardiotoxicity of liposomal doxorubicin, the risk of cardiac damage persists in anthracycline-pretreated individuals and mandates close cardiac monitoring and careful evaluation of the overall cumulative dose. 相似文献119.
M. Kay Garcia Jennifer McQuade Richard Lee Robin Haddad Michael Spano Lorenzo Cohen 《Current oncology reports》2014,16(12):1-9
In a previous systematic review of the worldwide literature of randomized controlled trials (RCTs) involving needle insertion into acupuncture points for symptom management in cancer patients, we identified only one high-quality RCT that was deemed to have a low risk of bias. Medline, Embase, CINAHL, Cochrane (all databases), Scopus, and PubMed were searched from inception through December 2011 with no language limits applied. A total of 41 RCTs met all inclusion criteria and were rated. In the current review, we examined 18 trials published since our last report. The purpose of this update was to emphasize important recent findings and discuss how concerns such as blinding, separating non-specific placebo effects from specific needling effects, determining biologic mechanisms and dosing parameters, evaluating determinants of response such as expectation, controlling for sources of bias, and the lack of standardization in treatment and study methods may affect the interpretation of study results. 相似文献
120.
Alba A. Brandes Enrico Franceschi Alicia Tosoni Stefania Bartolini Antonella Bacci Raffaele Agati Claudio Ghimenton Sergio Turazzi Andrea Talacchi Miran Skrap Gianluca Marucci Lorenzo Volpin Luca Morandi Stefano Pizzolitto Marina Gardiman Alvaro Andreoli Fabio Calbucci Mario Ermani 《Neuro-oncology》2010,12(3):283-288
O6-methylguanine DNA-methyltransferase (MGMT) promoter methylation status is a prognostic factor in newly diagnosed glioblastoma patients. However, it is not yet clear whether, and if so how, MGMT methylation status may change. Moreover, it is unknown whether the prognostic role of this epigenetic feature is retained during the disease course. A retrospective analysis was made using a database of 614 glioblastoma patients treated prospectively from January 2000 to August 2008. We evaluated only patients who met the following inclusion criteria: age ≥18 years; performance status 0-2; histological diagnosis of glioblastoma at both first and second surgery for recurrence; postoperative treatment consisting of: (i) radiotherapy (RT) followed by adjuvant temozolomide (TMZ) until 2005 and (ii) TMZ concurrent with and adjuvant to RT after 2005; a time interval ≥3 months between first and second surgery. MGMT status was evaluated at first and second surgery in all 44 patients (M:F 32:12, median age: 49 years, range: 27–67 years). In 38 patients (86.4%), MGMT promoter status was assessable at both first and second surgery. MGMT methylation status, changed in 14 patients (37%) of second surgery samples and more frequently in methylated than in unmethylated patients (61.5% vs 24%, P = .03). The median survival was significantly influenced only by MGMT methylation status determined at first surgery (P = .04). Significant changes in MGMT methylation status during the course of GBM occur more frequently in MGMT methylated than unmethylated cases. MGMT methylation status determined at first surgery appears to be of prognostic value; however, it is not predictive of outcome following second surgery. 相似文献